Method of treating movement disorders using barbituric acid derivatives
Patent 7655667 Issued on February 2, 2010. Estimated Expiration Date: February 16, 2026. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
A method of treating movement disorders comprises administering to a human or animal subject in need of treatment a therapeutically effective amount of at least one compound according to the following formula: wherein R3 and R4 are each independently selected from the group consisting of lower alkyl, phenyl and lower alkyl substituted phenyl, and R1 and R2 are each independently either a hydrogen atom or a radical of the formula wherein R5 and R6 are each independently selected from the group consisting of H, lower alkyl, phenyl and lower alkyl substituted phenyl, its pharmaceutically acceptable salts, prodrugs, and metabolites thereof.
Other References
Vida et al., “Anticonvulsants. IV. Metharbital and phenobarbital derivatives” Journal of Medicinal Chemistry, vol. 16, No. 12, pp. 1378-1381, 1973.
Ropper et al., “Adams and Victor's Principles of Neurology” (8th ed., 2005), pp. 338-339, 895-958.
Zavadil et al., Effects of Diphenylbarbituric Acid on Neuromuscular and Spinal Cord Function in the Cat, Neuroscience Abstracts, p. 694 (1975).
Office Action Issued by the USPTO on Apr. 20, 2009, for U.S. Appl. No. 11/201,024.
Office Action Issued by the USPTO on Feb. 25, 2009, for U.S. Appl. No. 11/355,336.
Office Action Issued by the USPTO on Mar. 24, 2009, for U.S. Appl. No. 11/169,044.
Constantino et al., “Metabotropic glutamate receptors: targets for therapy of cerebral ischaemia,” Expert Opinion on Therapeutic Drugs, vol. 5, pp. 669-683, 2001.
Office Action issued by the USPTO on Apr. 22, 2009 for U.S. Appl. No. 10/865,428.
IUPAC, Glossary of terms used in Medicinal Chemistry, pp. 1-10, 1998.
Broderick et al., “Guidelines for the Management of Spontaneous Intracerebral Hemorrhage,” Stroke, vol. 30, pp. 905-915, 1999.
Written Opinion issued in PCT Application No. PCT/US04/041138, mailed on Aug. 10, 2005.
International Search Report issued in PCT Application No. PCT/US04/041138, mailed on Aug. 10, 2005.
Office Action issued by the USPTO on Jan. 11, 2008 for U.S. Appl. No. 11/727,557.
Office Action issued by the USPTO on Dec. 5, 2007 for U.S. Appl. No. 11/201,024.
Office Action issued by the USPTO on Oct. 5, 2007 for U.S. Appl. No. 11/355,336.
Office Action issued by the USPTO on Nov. 1, 2007 for U.S. Appl. No. 10/865,428.
Pharmaceutical Chemistry, Mar. 7, 1981.
Vida J. et al., “Anticonvulsants. 2. Acyloxymethyl and halomehtyl derivaitives of barbituric acid and diphenylhydantoin”, Journal of Medicinal Chemistry, 14(3): p. 190-193, Mar. 1971.
Casagrande, C. et al., “Synthesis and antiarrhythmic activity of 5,5-disubstituted-3-aminoalkylhydantoins and some heterocyclic and noncyclic analogs”, retrieved from STN Database accession No. 1975:43261, Farmaco, Edizione Scientific, 29(10) 757-785, 1974.
Selleri, R. et al., “N1, N3-Disubstituted barbituric acid derviates of ganglioplegic or curarelike action”, retrieved from STN Database accession No. 1959:111820, Farmaco, Edizione Scientifica, 12, 3-14, 1957.
Werner W. et al., “Structure effect interactions in Mannich bases with and without nitrogen mustard groups and some reference compounds as potential immunosuppressive agents”, retrieved from STN Database accession No. 85: 72035, Pharmazie 31(5) 282-7, 1976.
Vida J. A. et al, “Anticonvulsants. III. Phenobarbital and mephobarbital derivatives”, Journal of Medicinal Chemistry 1973, vol. 16, p. 602-605.
Vida J. A. et al, “Anticonvulsants. IV. Metharbital and phenobarbital derivatives” Journal of Medicinal 1378-1381.
Rekling Jens C., “Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation”, Neuroscience Letters, vol. 335, No. 3, Jan. 2, 2003, pp. 167-170.
Malhotra, S. et al., “T-2000, a novel non-sedating barbiturate reduces infact size and improves neurologic functions following MCAO in the rat,” Program No. 821.10. 2004 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2004. Online.
Kojima et al., J. Pharm Sci. 60: 1639-1641 (1971).
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., 373-380 (1996).
International Preliminary Report on Patentability issued in PCT Application No. PCT/US2005/028380, issued on Feb. 13, 2007.
International Preliminary Report on Patentability issued in PCT Application No. PCT/IL2005/000697, issued on Jan. 9, 2007.
International Preliminary Examination Report issued in PCT Application No. PCT/US03/039530, completed on Mar. 10, 2005.
International Preliminary Examination Report issued in PCT Application No. PCT/US03/02638, completed on Oct. 31, 2003.
International Preliminary Examination Report issued in PCT Application No. PCT/US01/23420, completed on Feb. 23, 2003.
International Search Report issued in PCT Application No. PCT/US2005/028380, mailed on Dec. 8, 2006.
International Search Report issued in PCT Application No. PCT/IL2005/000697, mailed on Oct. 13, 2006.
International Search Report Issued in PCT Application No. PCT/US03/02638, mailed on Jun. 18, 2003.
International Search Report Issued in PCT Application No. PCT/US01/23420, mailed on Nov. 20, 2001.
International Search Report Issued in PCT Application No. PCT/US98/20665, mailed on Apr. 2, 1999.
European Search report issued in EP Application No. 05 78 6192 , dated Nov. 22, 2007.
European Search report issued in EP Application No. 03 73 5068, dated Feb. 28, 2006.
European Search report issued in EP Application No. 03 01 1817, completed Jul. 14, 2003.
European Search report issued in EP Application EP 01 95 9195, dated Feb. 24, 2006.
European Search report issued in EP Application EP 05 29 0804, dated Jun. 16, 2005.
Zavadil Ill, et al. “Diphenylbarbituric Acid” (Epilepsia) 1985, 26: 158-166.
Yeh et al. “A comparison of numerical integrating algortihms by trapezoidal, lagrange, and spline approximations.” (J. Pharmacokinet Biopharm) 1978, 6: 79.
Whittle et al. “Differential effect of sedative and anticonvulsant barbiturates on specific gaba binding to membrane prep . . . ” (Bio. Pharmacology) 1982, 31: 2891-2895.
Weinryb et al., Chemical Abstracts, 76:1206c, 1972.
The New England Journal of Medicine, vol. 345, No. 12, Sep. 2001 pp. 887-891, Elan D. Louis, “Essential Tremor”.
The New England Journal of Medicine, vol. 339, No. 16, Oct. 1998, pp. 1130-1143, Anthony E. Lang, et al. “Parkinson's Disease”, Second of Two Parts.
The Merck Index, 10th Ed., (Merck & Co., Inc., Rahway, NJ) (1983) p. 544 (entry 3694).
Thacker et al., “Method for the Determination of 5,5-Diphenylbarbituric Acid and Separation from 1,3-Dimethoxymethyl-5,5-Diphenylbarbituric Acid in Plasma by High Performance Liquid Chromatography,” J. Chromatography B. 710:149-155 (1998).
Tagmann et al., Helv. Chim. Acta 35, 1541-1549 (1952).
Swanson et al., “Barbiturates impair astrocyte glutamate uptake,” GLIA, Dec. 1998, vol. 34, No. 4, Dec. 1998, pp. 365-371.
Sturfelt, G. et al.: Acute Effects of Barbiturates in Parkinson's Disease, “Acta Medica Scandinavica, Almqvist & Wiksell Periodical Co.;” Stockholm, SE, vo. 201, No. 1/2, 1977, pp. 75-76, XP000937405.
Stavber et al., Chemical Abstracts, 99:157381s, 1983.
Sircar, “CLXXIII.—The Influence of Groups and Associated Rings on the Stability of Certain Heterocyclic Systems. Part II. The Substituted Succinimides”; Journal of the Chemical Society , May 1927, pp. 1252-1258.
Shapiro, “Barbiturates in Brain Ischaemia,” British Journal of Anaesthesia, BJM Publishing Group, London, Great Britain, vol. 57, No. 1, Jan. 1985, pp. 82-95.
Serrano et al. “Intramuscular administration of diphenylhydantoin” Arch. Neurol., Oct. 1974, 31: 276-277.
Samour et al., “Anticonvulsants, 1. Alkoxymethyl Derivatives of Barbiturates and Diphenylhydantoin”, Journal of Medicinal Chemistry, 14(3), pp. 187-189, (1971).
Salmon-Legagneur et al., “Sur les acides α-pheyl α-alcoyl (ou phenoalcoyl) glutariques”, Comptes Rendus de I'Academie des Sciences, (Mar. 3, 1952) p. 1060.
Salmon-Legagneur et al., “Recherches dans la serie des diacides αα-disubstitues et de leurs derives. III. Les acides α-phenol α-alcoyl (ou phenoalcoyl) glutariques et leurs principaux derives”, Bull. Soc. Chim. France (1953) p. 70.
Rev. Neurol., 2001, 32 (6): 520-524; I. Balas et al. “Talamotomia esterotaxica de la enfermedad de Parkinson y otros tipos de temblor. Experiencias de la actividad multiunitaria burst en el talamo basada en semimicroelectrodos”. (English Abstract).
Remington: The Science and Practice of Pharmacy, 20th Edition; Published 2000 by Lippincott Williams and Wilkins, Edited by Daniel Limmer, pp. 317-322.
Raines et al., Chemical Abstracts, 92:174402x, 1980.
Raines et al., Chemical Abstracts, 79:87539k, 1973.
Raines et al., “The Effects of 5,5-Diphenylbarbituric Acid on Experimental Seizures in Rats: Correlation between Plasma and Brain Concentrations and Anticonvulsant Activity,” Epilepsia, 16:575-581 (1975).
Raines, et al. ,“Serum and Brain Levels of 5-5-Diphenylbarbituric Acid (DPB) After Administration of dimethoxymethyl-Diphenylbarbituric Acid (DMMDPB) in the Rat,” Epilepsia, 37:Supp. 5, p. 23, Abstract 1.84 (1996).
Raines et al. “Pre and postjunctional effects of diphenylhydantoin at the cat soleus neuromuscular junction” (J. Pharmacol Exp. Ther.) 1966, 153: 361-366.
Raines et al., “Conversion of Dimethoxymethyl-Diphenylbarbituric Acid (DMMDPB) to Diphenylbarbituric Acid (DPB) in the rat,” The FASEB J., 1996, Abstract No. 895.
Raines et al., “Conversion of Dimethoxymethyl-Diphenylbarbituric Acid (DMMDPB) to Diphenylbarbituric Acid (DPB) in the Dog,” The FASEB J., 13(4):A475, Abstract 394.2 (1999).
Raines et al., “Anticonvulsant properties of 5,5-diphenylbarbituric acid (DPB)” (Pharmacology) 1973, 32: 3246.
Raines et al., “A Comparison of the Anticonvulsant, Neurotoxic and Lethal Effects of Diphenylbarbituric Acid Phenobarbital and Diphenylhydantoin in the Mouse,” J. Pharmacology and Experimental Therapeutics, 186(2):315-322 (1973).
Pulsinelli et al., “Temporal profile of neuronal damage in a model of transient forebrain ischemia”, Annals of Neurology, May 11(5), 491-498, (1982).
Pulsinelli and Brierley, “A new model of bilateral hemispheric ischemia in the unanesthetized rat”, Stroke, May-Jun. 10(3), pp. 267-272, (1979).
PubMed search results printout of Dec. 27, 2002 (total of 3 pages).
Prankerd et al. “Physio-chemical properties of barbituric acid derivatives: IV. Solubilities of 5,5-disubstituted barbituric acids . . . ” (Int. J. Pharmaceutics) 1994, 112: 1-15.
Piatt, et al., “High dose barbiturate therapy in neurosurgery and intensive care,” Neurosurgery, vol. 15, No. 3, Sep. 1984, pp. 427-444.
Parkinson's Disease and Movement Disorders, Urban & Schwarzenberg, Inc., 1988, 17: 225-234, Stanley Fahn, et al. “Clinical Rating Scale for Tremor”.
Ondo, W. et al.: “Essential tremor. Treatment Options,” CNS Drugs 1996 New Zealand, vol. 6, No. 3, 1996, pp. 178-191, XP009032012.
Nims et al. “Compartive pharmacodynamics of hepatic cytochrome P450 2B induction by 5,5-diphenyl- and 5,5-diethyl substituted . . . ” (J. Pharmacol. Exp. Ther.) 1994, 270: 348-355.
Neurology, Jun. 2000, vol. 54, Suppl 4, S8-S13, Leslie J. Findley, “Epidemiology and Genetics of Essential Tremor”.
Neurology, Jun. 2000 vol. 54, Supp.I 4, S30-S38, William C. Koller et al., “Pharmacologic Treatment of Essential Tremor”.
Neurology, 1988, 38:808-810, “Double-Blind Comparison of Primidone and Phenobarbital In Essential Tremor”; Enrico Sasso, et al.
Neurology, 1986; 36:121-124, “Efficacy of Primidone In Essential Tremor”, William C. Koller, et al.
Neurology, 1985, 35:1784-1787, “Phenobarbitone in Essential Tremor”, Leslie J. Findley, et al.
Movement Disorders, vol. 6, No. 1, 1991, pp. 65-68, “Quantitative Comparison of Barbiturates in Essential Hand and Head Tremor”, Enrico Sasso, et al.
Movement Disorders, vol. 16, No. 3, 2001 pp. 464-468, William C. Koller, et al. “Long Term Safety and Efficacy of Unilateral Deep Brain Stimulation of the Thalamus in Essential Tremor”.
Movement Disorders, vol. 13, Suppl 3., pp. 90-100, 1998, Paul G. Wasielewski, et al. “Pharmacologic Treatment of Tremor”.
Movement Disorders 2, 1987, (22) 438-458, Leslie J. Findley, “The Pharmacology of Essential Tremor”.
Modern Pharmacology, 2nd Ed., 1986, Ch. 4, pp. 41-64, Theodore E. Gram “Metabolism of Drugs”.
Merritt et al. “Experimental determination of anticonvulsive activity of chemical compounds” (Epilepsia) 1945, 3: 51-75.
McKeown et al. “Thermodynamic functions for dissociation of 5,5-disubstituted barbituric acids- their signficance in structure-reactivity . . . ” (Ellis Horwood) 1986, 6: 80-89.
Mayo Clinic Proceedings, vol. 66, No. 10, Oct. 1991, pp. 991-997, Manfred D. Muenter, et al. “Treatment of Essential Tremor With Methazolamide”.
Masuda et al., “Relationships Between Plasma Concentrations of Diphenylhydantoin, Phenobarbital, Carbamazepine, and 3-Sulfamoylmethyl- 1,2-Benzisoxazole (AD-810), a New Anticonvulsant Agent, and Their Anticonvulsant or Neurotoxic Effects in Experimental Animals”, Epilepsia, 20, pp. 623-633, (1979).
Lightfoote, et al., Stroke, 8, pp. 627-628, (1977).
Levy and Brierley, “Delayed pentobarbital administration limits ischemia brain damage in gerbils”, Annals of Neurology, 5(1), pp. 59-64, (1979).
Knoefel et al. “The anticonvulsant action of diphenylhydatoin and some related compounds” (J. Pharmacol Exp. Ther.) 1942, 76: 194-201.
Karger et al., “Methoxymethyl Methanesulfonate, A Novel Active Oxyalkylating Agent,” J. Am. Chem. Soc., 91:5663 (1969).
Kamata et al., “Studies of Antitumor-Active 5-Fluorouracil Derivatives I Synthesis of N-Phthalidyl 5-Fluorouracil Derivatives”, Chem. Pharm. Bull, 33 (8), pp. 3160-3175, (1985).
Journal of Neurology, Neurosurgery, and Psychiatry 1986;49:64-68, “A Comparison of Primidone, Propranolol, and Placebo in Essential Tremor, Using Quantitative Analysis”, W.P. Gorman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry 1985;48:911-915, “Primidone in Essential Tremor of the Hands and Head: A Double Blind Controlled Clinical Study”, Leslie J. Findley, et al.
JAX® Mice Literature, “Ask the Vet” No. 499 Published online in fall 2005 at http://jaxmice.jax.org/library/notes/499c.html.
International Search Report issued in PCT Application No. PCt/US03/39530, mailed on Jul. 7, 2004.
Iadarola et al. “Comparison of the effects of diphenylbarbituric acid, phenobarbital, pentobarbital and secobarbital . . . ” (J. Pharmacol Exp. Ther.) 1985, 232: 127-133.
Hoff et al., Stroke, 6, pp. 28-33, (1975).
Hamann, M. et al.: “Effects of striatal injections of GABAA receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia,” European Journal of Pharmacology, vol. 443, No. 1-3, May 17, 2002, pp. 59-70, XP002284223.
Goodman & Gilman's “The Pharmacological Basis of Therapeutics 2001” p. 412-419, 10th Ed.
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed. Ch. 17, 361-396, William R. Hobbs et al., “Hypnotics and Sedatives; Ethanol”.
Glazko et al. “Early adventures in drug metabolism: 2. The absorption of drugs” (Ther. Drug Monit.) 1987, 9: 180-89.
Ginsberg, “Animal Models of Global and Focal Cerebral Ischemia,” Chapter 34 in Welsh Kma et al., Primer on Cerebrovascular Diseases, Academic Press, New York (1997).
Gibaldi et al. “Pharmokinetics Second Ed.” 2nd Ed Marcel Dekker, Inc. 1982.
Gesson et al., “A practical method for N-alkylation of succinimide and glutarimide”, Bull Soc. Chim. Fr. 129, pp. 227-231, (1992).
Garcia et al., “Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the caudoputamen and the cortex”, Stroke, 26(4), 636-643 (1995).
Garcia et al., “Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation”, Stroke, 26(4), pp. 627-634, (1995).
Gao et al., “Physical Chemical Stability of Warfarin Sodium,”AAPS Pharmasci (2001) 3(1) Article 3.
Foye, “Principles of Medicinal Chemistry,” 3rd ed. (1990) pp. 164, 179.
Fink et al. “Modification of maximal audiogenic and electroshock seizures in mice by psychopharmacologic drugs” (J. Pharmacol Exp. Ther.) 1959, 127: 318-324.
Dox et al “5,5-Diarylbarbituric Acids” (J. Chem. Soc.) 1923, 45: 1811-1816.
Corkill et al., Surg. Neurol., pp. 147-149 (1976).
Craig et al. “Metabolism and anticonvulsant properties of mephobarbital and phenobarbital in rats” (J. Pharmacol Exp. Ther.) 1971, 176: 35-41.
Clinician, May 2001, vol. 19, No. 2, pp. 1-15, “Essential Tremor: A Practical Guide to Evaluation, Diagnosis, and Treatment”.
Clinical Neuropharmacology, vol. 13, No. 3, 1990, pp. 210-223, “Basic Mechanism of Action of Drugs Used in the Treatment of Essential Tremor”, Xiao-Ming Guan, et al.
Clinical Neuropharmacology, vol. 13, No. 1, 1990, pp. 67-76, “Primidone in the Long-Term Treatment of Essential Tremor: A Prospective Study with Computerized Quantitative Analysis”, Enrico Sasso, et al.
Clinical Neuropharmacology vol. 10, No. 4, 1987, pp. 342-350, Essential Tremor Variants: Effect of Treatment, William C. Koller, et al.
Casara et al., “Synthesis of acid stable fluorinated acyclonucleosides as potential antiviral agents,” Tetrahedron Letters, 32(31) (1991), pp. 3823-3826.
C.D. Marsden, Origins of Normal and Pathological Tremor in Movement Disorders: Tremor. Eds. L.J. Findley and R. Capildeo, New York, Oxford University Press, 1984, pp. 37-84 “Origins of Normal and Pathological Tremor”.
Brint et al., “Focal brain ischemia in the rat: Methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries”, J. Cerebral Blood Flow Metab., 8, pp. 474-485, (1988).
Breimer et al. “Pharmacokinetics and relative bioavailbility of heptabarbital and heptabarbital sodium after oral administration to man” (Eur. J. Clin. Pharmacology) 1975, 9: 169-178.
Boron Tribromide, Encyclopedia of Reagents for Organic Synthesis edited by Leo Pacquette, pp. 1-9, 2003.
Bhardwaj et al., “Pentobarbital inhibits extracellular release of dopamine in the ischemic striatum”, Journal of Neural Transmission [Gen Sect], 82, pp. 111-117, (1990).
Bertram et al., “Phenobarbital is superior to phenytoin as an antiepileptic, neuroprotectant and antiepileptogenic agent in a rat model of status epilepticus and chronic limbic epilepsy,” Epilepsia, vol. 37, No. Suppl. 5, p. 140 (1996); and Annual Meeting of the American Epilepsy Society, San Francisco, CA, USA, Dec. 7-10, 1996.
Baumel et al. “Metabolism and anticonvulsant properties of primidone in the rat” (J. Pharmacol Exp. Ther.) 1973, 186: 305-314.
Barnes, Harry M. and McElvain, S. M. “For Further Observations on the Condensation of Benzene with Alloxan” (J. Am. Chem. Soc.) Jul.-Dec. 1937, 59: 2348-2351.
Bashir, K. et al.: “Clozapine for the control of hemiballismus,” Clinical Neuropharmacology, vol. 17, No. 5, 1994, pp. 477-480, XP009032005.
Archives of Neurology, Apr. 1999, vol. 56, No. 4: 475-480, Alexandre Gironell, et al., “A Randomized Placebo-Controlled Comparative Trial of Gabapentin and Propranolol in Essential Tremor”.
Arch Otolaryngol, vol. 110, Jun. 1984, pp. 394-397, “Spastic Dysphonia and Essential (Voice) Tremor Treated With Primidone”, David E. Hartman, et al.
Appendix 3 of U.S. Appl. No. 60/352,273, filed Jan. 30, 2002: PubMed search results printout of Jan. 15, 2002 (total of 7 pages).
Appendix 3 of U.S. Appl. No. 60/352,273, filed Jan. 30, 2002: MEDLINEplus printout of Jan. 15, 2002: Barbiturates (Systemic) (total of 14 pages).
Appendix 3 of U.S. Appl. No. 60/352,273, filed Jan. 30, 2002: Cancerlit . . . (total of 9 pages).
Appendix 2 of U.S. Appl. No. 60/352,273, filed Jan. 30, 2002: References to Chemical Derivatives (total of 3 pages).
Appendix 1 of U.S. Appl. No. 60/352,273, filed Jan. 30, 2002: Chemical Derivative Chart (total of 8 pages).
Alles et al. “Comparative central depressant actions of some 5-phenyl-5-alky barbituric acids” (J. Pharmacol Exp. Ther.) 1947, 89: 356-367.
Aldrich Chemical Catalog, 1990-1991, p. 303.
Acta Neurol Scand., 1987:75:332-340, “Primidone and Propranolol in Essential Tremor: A Study Based on Quantitative Tremor Recording and Plasma Anticonvulsant Levels”, P. Dietrichson, et al.
McElvain, “5,5-diphenylbarbituric acid” J. Am. Chem. Soc. (1935) vol. 57, pp. 1303-1304.
Raines et al., “Differential Selectivity of Severla Barbiturates on Experimental Seizures and Neurotoxicity in the Mouse” Epilepsia (1979) vol. 20, pp. 105-113.
“Remington: The Science and Practce of Pharmacy” 20th edition, published 2000 by Lippincott Williams and Wllkins, pp. 704-714, 743-747, and 858-863.
Berge et al. “Pharmaceutical Salts” Journal of Pharmaceutical Sciences (1977) vol. 66, No. 1, pp. 1-19.
Merck Manual of Diagnosis and Therapy, Seventeenth Edition, Beers et al., ed., (1999), Chapter 179, pp. 1462-1473.
February 16, 2026. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
